MedTrace Logo

Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL)

NCT02531308 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2022-09-28

Study results available
· View outcomes & findings →

Summary

Evaluation of impact of metformin on 2 year progression-free survival (PFS) rate in subjects with previously untreated DLBCL when added to standard induction therapy. (R-CHOP)

Conditions

  • Diffuse Large B-Cell Lymphoma

Interventions

DRUG

Metformin

Metformin upregulates AMPK activity which has been shown to have an anti-proliferative effect on lymphoma cells.

DRUG

Rituximab

monoclonal antibody against protein CD20 primarily found on the surface of B-cells

DRUG

Cyclophosphamide

Interferes with DNA replication

DRUG

Doxorubicin

anthracycline antitumor antibiotic

DRUG

Vincristine

Inhibits cell mitosis causing cell death.

DRUG

Prednisone

a synthetic corticosteroid drug that is particularly effective as an immunosuppressant drug. It is used to treat certain inflammatory diseases

DRUG

pegfilgrastim

stimulates the level of white blood cells (neutrophils).

Sponsors & Collaborators

  • Rush University Medical Center

    lead OTHER

Principal Investigators

  • Reem Karmali, MD · Assistant Professor of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2016-07-31
Completion
2016-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02531308 on ClinicalTrials.gov